Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet®/Dovobet®/Taclonex®) in the treatment of psoriasis vulgaris

Dermatology

Volumn 213, Issue 4, 2006, Pages 319-326

  Kragballe, K ^a   Austad, J ^b   Barnes, L ^c   Bibby, A ^d   De La Brassinne, M ^e   Cambazard, F ^f   Fleming, C ^g   Heikkila H ^h   Williams, Z ^d   Peyri Rey, J ⁱ   Svensson, A ^j   Toole, J ^k   Wozel, G ^l  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Hudlegekontoret   (Norway)

^c ST JAMES S HOSPITAL   (Ireland)

^d Leo Pharmaceuticals   (United Kingdom)

^e UNIVERSITY OF LIÈGE   (Belgium)

^f HÔPITAL NORD   (France)

^g PERTH ROYAL INFIRMARY   (United Kingdom)

^h HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

ⁱ HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^j LUND UNIVERSITY HOSPITAL   (Sweden)

^k Dermadvances Research   (Canada)

^l UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

more..

Author keywords

Daivobet ; Dovobet ; Psoriasis; Taclonex ; Two compound product

Indexed keywords

BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CALCIPOTRIOL; TACLONEX;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OINTMENT; PRIORITY JOURNAL; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

ANTI-INFLAMMATORY AGENTS; BETAMETHASONE; CALCITRIOL; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PSORIASIS; SAFETY; TIME FACTORS; TREATMENT OUTCOME;

EID: 33751532623     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096069     Document Type: Article

References (20)

1. Greaves MW, Weinstein GP: Treatment of psoriasis. N Engl J Med 1995;332:581-588.
2. Rapp SR, Feldman SR, Exum ML, Fleischer AB, Reboussin DM: Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401-407.
3. Kaufmann R, Bibby AJ, Bissonnette R, Cambazard F, Chu AC, Decroix J, Douglas WS, Lowson D, Mascaro JM, Murphy GM, Stymne B: A new calcipotriol/betamethasone dipropionate formulation (Daivobet™) is an effective once-daily treatment for psoriasis vulgaris. Dermatology 2002;205:389-393.
4. Papp KA, Guenther L, Boyden B, Larsen FG, Harvima RJ, Guilhou JJ, Kaufmann R, Rogers S, van de Kerkhof PCM, Hanssen LI, Tegner E, Burg G, Talbot D, Chu A: Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 2003;48:48-54.
5. Douglas WS, Poulin Y, Decroix J, Ortonne JP, Mrowietz U, Gulliver W, Krogstad AL, Larsen FG, Iglesias L, Buckley C, Bibby AJ: A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol 2002;82:131-135.
6. Kragballe K, Noerrelund KL, Lui H, Ortonne JP, Wozel G, Uurasmaa T, Fleming C, Lopez Estebaranz JL, Hanssen LI, Persson LM: Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol 2004;150:1167-1173.
7. Ashcroft DM, Li Wan Po A, Griffiths CEM: Therapeutic strategies for psoriasis. J Clin Pharmacol Ther 2000;25:1-10.
8. Ramsay CA, Berth-Jones J, Brundin G, Cunliffe WJ, Dubertret L, van de Kerkhof PCM, Menne T, Wegmann E: Long-term use of topical calcipotriol in chronic plaque psoriasis. Dermatology 1994;189:260-264.
9. Poyner T, Hughes JW, Dass BK, Adnitt PI: Long term treatment of chronic plaque psoriasis with calcipotriol. J Dermatol Treat 1993;4:173-177.
10. Ellis JP, Griffiths WAD, Klaber MR: Long-term treatment of chronic plaque psoriasis with calcipotriol ointment in patients unresponsive to short contact dithranol. Eur J Clin Res 1995;7:247-257.
11. Kragballe K, Austad J, Barnes L, Bibby A, de la Brassinne M, Cambazard F, Fleming C, Heikkila H, Jolliffe D, Peyri J, Svensson A, Toole J, Wozel G: A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet®/Daivobet®/Taclonex®) in the treatment of psoriasis vulgaris. Br J Dermatol 2006;154:1155-1160.
12. International Conference on Harmonisation: Harmonised Tripartite Guideline. The extent of population exposure to assess clinical safety for drugs intended for long-term treatment of non-life-threatening conditions: E1. http://www.ich.org/LOB/media/MEDIA435.pdf.
13. Liem WH, McCullough JL, Weinstein GD: Effectiveness of topical therapy for psoriasis: results of a national survey. Cutis 1995;55:306-310.
14. Svartholm H, Larsson L, Frederiksen B: Intermittent topical treatment of psoriasis with clobetasol propionate ('Dermovate'). Curr Med Res Opin 1982;8:154-157.
15. Katz HI, Prawer SE, Medansky RS, Krueger GG, Mooney JJ, Jones ML, Samson CR: Intermittent corticosteroid maintenance treatment of psoriasis: a double-blind multicenter trial of an augmented betamethasone dipropionate ointment in a pulse dose treatment regimen. Dermatologica 1991;183:269-274.
16. Katz HI, Hien NT, Prawer SE, Scott JC, Grivna EM: Betamethasone dipropionate in optimized vehicle. Intermittent pulse dosing for extended maintenance treatment of psoriasis. Arch Dermatol 1987;123:1308-1311.
17. Miller JJ, Roling D, Margolis D, Guzzo C: Failure to demonstrate therapeutic tachyphylaxis to topically applied steroids in patients with psoriasis. J Am Acad Dermatol 1999;41:546-549.
18. Hanifin JM, Cooper KD, Ho VC, Kang S, Krafchik BR, Margolis DJ, Schachner LA, Sidbury R, Whitmore SE, Sieck CK, Van Voorhees AS: Guidelines of care for atopic dermatitis. J Am Acad Dermatol 2004;50:391-404.
19. Noerregaard J, Lowson D: The cost-utility of calcipotriol/betamethasone (Dovobet) ointment in the treatment of psoriasis vulgaris in the United Kingdom (abstract). Value in Health 2003;6:785.
20. Peeters P, Ortonne J-P, Sitbon R, Guignard E: Cost-effectiveness of once-daily treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol in the treatment of psoriasis vulgaris. Dermatology 2005;211:139-145.